Transdermal permeation enhancers are compounds that temporarily increase drug flux through the skin by interacting with constituents of the stratum corneum. Transkarbam 12 (T12) is a highly active, broad-spectrum, biodegradable enhancer with low toxicity and low dermal irritation. We show here that T12 acts by a dual mechanism of action. The first part of this activity is associated with its ammonium carbamate polar head as shown by its pH-dependent effects on the permeation of two model drugs. Once this ammonium carbamate penetrates into the stratum corneum intercellular lipids, it rapidly decomposes releasing two molecules of protonated dodecyl 6-aminohexanoate (DDEAC) and carbon dioxide. This was observed by thermogravimetric analysis and infrared spectroscopy. This step of T12 action influences drug permeation through lipidic pathways, not through the aqueous pores (polar pathway) as shown by its effects on various model drugs and electrical impedance. Consequently, protonated DDEAC released in the stratum corneum is also an active enhancer. It broadens the scope of T12 action since it is also able to increase permeation of hydrophilic drugs that prefer the pore pathway. Thus, this dual effect of T12 is likely responsible for its favorable properties, which make it a good candidate for prospective clinical use.

Faculty of Pharmacy Centre for New Antivirals and Antineoplastics Charles University Prague Heyrovského 1203 50005 Hradec Králové Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc12027925

003      

CZ-PrNML

005      

20121207114448.0

007      

ta

008      

120817s2011 ne f 000 0#eng||

009      

AR

024    7_

$a 10.1016/j.jconrel.2010.11.017 $2 doi

035    __

$a (PubMed)21093505

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ne

100    1_

$a Novotný, Michal $u Faculty of Pharmacy, Centre for New Antivirals and Antineoplastics, Charles University in Prague, Heyrovského 1203, 50005 Hradec Králové, Czech Republic.

245    10

$a Ammonium carbamates as highly active transdermal permeation enhancers with a dual mechanism of action / $c M. Novotný, J. Klimentová, B. Janůšová, K. Palát, A. Hrabálek, K. Vávrová,

520    9_

$a Transdermal permeation enhancers are compounds that temporarily increase drug flux through the skin by interacting with constituents of the stratum corneum. Transkarbam 12 (T12) is a highly active, broad-spectrum, biodegradable enhancer with low toxicity and low dermal irritation. We show here that T12 acts by a dual mechanism of action. The first part of this activity is associated with its ammonium carbamate polar head as shown by its pH-dependent effects on the permeation of two model drugs. Once this ammonium carbamate penetrates into the stratum corneum intercellular lipids, it rapidly decomposes releasing two molecules of protonated dodecyl 6-aminohexanoate (DDEAC) and carbon dioxide. This was observed by thermogravimetric analysis and infrared spectroscopy. This step of T12 action influences drug permeation through lipidic pathways, not through the aqueous pores (polar pathway) as shown by its effects on various model drugs and electrical impedance. Consequently, protonated DDEAC released in the stratum corneum is also an active enhancer. It broadens the scope of T12 action since it is also able to increase permeation of hydrophilic drugs that prefer the pore pathway. Thus, this dual effect of T12 is likely responsible for its favorable properties, which make it a good candidate for prospective clinical use.

650    _2

$a kyselina 6-aminokapronová $x analogy a deriváty $x chemie $x metabolismus $x farmakologie $7 D015119

650    _2

$a adjuvancia farmaceutická $x chemie $x metabolismus $x farmakologie $7 D000277

650    _2

$a aplikace kožní $7 D000279

650    _2

$a zvířata $7 D000818

650    _2

$a karbamáty $x chemie $x metabolismus $x farmakologie $7 D002219

650    _2

$a oxid uhličitý $x chemie $x metabolismus $7 D002245

650    _2

$a elektrická impedance $7 D017097

650    _2

$a epidermis $x chemie $7 D004817

650    _2

$a hydrokortison $x aplikace a dávkování $x metabolismus $7 D006854

650    _2

$a koncentrace vodíkových iontů $7 D006863

650    _2

$a lipidy $x chemie $x izolace a purifikace $7 D008055

650    _2

$a kyselina palmitová $x chemie $7 D019308

650    _2

$a permeabilita $x účinky léků $7 D010539

650    _2

$a kůže $x účinky léků $x metabolismus $7 D012867

650    _2

$a kožní absorpce $x účinky léků $7 D012869

650    _2

$a fyziologie kůže $x účinky léků $7 D012879

650    _2

$a spektrofotometrie infračervená $7 D013055

650    _2

$a Sus scrofa $7 D034421

650    _2

$a theofylin $x aplikace a dávkování $x metabolismus $7 D013806

650    _2

$a termogravimetrie $7 D013818

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Klimentová, Jana

700    1_

$a Janůšová, Barbora

700    1_

$a Palát, Karel

700    1_

$a Hrabálek, Alexandr

700    1_

$a Vávrová, Kateřina

773    0_

$w MED00002621 $t Journal of controlled release : official journal of the Controlled Release Society $x 1873-4995 $g Roč. 150, č. 2 (2011), s. 164-70

856    41

$u https://pubmed.ncbi.nlm.nih.gov/21093505 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y m

990    __

$a 20120817 $b ABA008

991    __

$a 20121207114522 $b ABA008

999    __

$a ok $b bmc $g 949967 $s 785271

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2011 $b 150 $c 2 $d 164-70 $i 1873-4995 $m Journal of controlled release $n J Controlled Release $x MED00002621

LZP    __

$a Pubmed-20120817/11/03